Cell Therapy Market - North America, Europe, EMEA, APAC : US, Canada, China, Germany, UK - Forecast 2023-2027

Cell Therapy Market Forecast 2023-2027

The  Cell Therapy Market size is estimated to grow by USD 31.04 billion at a CAGR of 57.06% between 2022 and 2027. 

There is an increase in investments by several research institutes and pharmaceutical companies in cell-based drug development to offer better treatment options to patients. The main objective of this cell-based research is to find new drugs to stimulate the heart and enhance function. Additionally, there is an increasing focus by researchers on finding novel cell-based therapies for patients with corneal damage or cataracts and neurological conditions such as multiple sclerosis. For instance, The University of Florida, North Florida/South Georgia Veterans Health System, and Brooks Rehabilitation Hospital (all FL, USA) received USD 3,00,000 in January 2021 for the development of a regenerative rehabilitation strategy for spinal cord injuries. Hence, such factors are positively impacting the market.

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.

What will be the size of the Cell Therapy Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation by Type, Application, and Geography Analysis

The Diseseas Mechanisms and Interventions (DMI) report on the Cell Therapy market provides an in-depth analysis of the current trends, prospects, and growth opportunities in this field. The report covers various types of cell therapies, including progenitor cells, stem cells, and immune cells. The global cell therapy market is expected to grow significantly due to the rising prevalence of chronic diseases, increasing geriatric population, and technological advancements in the field. The regulatory environment is also favorable, with several regulatory bodies approving new cell therapy treatments. The market is segmented by application areas such as oncology, neurology, and regenerative medicine. The report also discusses the challenges and future prospects of the cell therapy market, including the high cost of treatment and ethical concerns. Overall, the cell therapy market is poised for robust growth in the coming years, driven by the increasing demand for personalized and effective treatments for various diseases.

Type Analysis 

Autologous

The autologous segment is estimated to witness significant growth during the forecast period. There is only a moderate growth of the autologous cell therapy segment due to its manufacturing complexities. Additionally, there is a low preference for this cell therapy in emergency care as it needs more time to generate autologous therapy cells.

Get a glance at the market contribution of various segments View a PDF Sample

The autologous segment was the largest segment and was valued at USD 444.45 million in 2017. There is an increase in the number of clinical trials for autologous cell therapy due to the fewer complications associated with it. The  market encompasses novel products designed to address various diseases by targeting disease mechanisms and disease progression. Despite the medium growth rate due to manufacturing complexities and less established clinical evidence, autologous cell therapies, including stem cell and gene therapies, are preferred in certain segments like dermatology and musculoskeletal disorders. Factors such as global population growth, climate change, and virus outbreaks fuel the need for advanced cell therapies. Key players like Thermo Fisher Scientific, Merck KGaA, Lonza, and Danaher dominate the market, focusing on cell processing, cell preservation, process monitoring, quality control, and cell banking facilities. Precision medicine and individual differences necessitate extensive research in cell biology and disease mechanisms, driving the development of new products and entry of small players. Regulatory guidelines and quality standards ensure survival and safety in oncology applications. Companies invest in funding and adhere to guidelines for cell banking, storage, and clinical trials, including EU grants, to advance treatment responses. Achilles Therapeutics is an example of a company pioneering innovative cell types in the fieldHence, such factors are expected to fuel the growth of this segment which in turn will drive the market during the forecast period.

Application Analysis 

Malignancies

The market is experiencing significant growth, particularly in the Oncology segment, driven by advancements in personalized medicine. Horizon Europe and research institutes are investing in stem cell therapy, including adult stem cells and cord blood processing. Companies like Sernova and Evotec are pioneering insulin-dependent diabetes treatments using stem cells. Automation and genetic editing tools, such as CRISPR-Cas9, are revolutionizing the industry. The Autologous therapy segment is gaining traction with CAR-T therapies for genetic disorders like acute lymphocytic leukemia. Pharmaceutical giants and biotechnology firms, including Panacell Biotech and Cellino Biotech, are collaborating on novel therapeutic regimes. The European Medicines Agency (EMA) and FDA have approved several cell therapies, including allogeneic therapies like ALLO-501, which harnesses the immune response to combat diseases like pneumonia. The market also caters to chronic conditions, such as diabetes, and musculoskeletal disorders. Immunosuppressive therapies and the graft-versus-cancer effect are crucial considerations in this field.v

Musculoskeletal

Musculoskeletal disorders significantly impact soft tissues including muscles, tendons, cartilage, and joint bones. The increasing prevalence of arthritis and sports-related injuries has fuelled the demand for cell therapy products. As a result, there is an increasing focus by companies on the development of cell therapy products that treat joints and soft tissues. For example, one of the prominent companies such as Mesoblast has developed MPC injections, which help to replace lost cartilage and proteoglycan in degenerated intervertebral discs. Hence, such factors are expected to fuel the growth of this segment which, in turn, will drive the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Some of the main factors that are significantly contributing to the growth of the global market in North America are increased funding from governments and the growing number of regenerative medicine centers in the region, especially in countries such as the US, Canada, and Mexico.

Moreover, one of the prominent markets in North America for the growth of the global market is the US due to the increased funding offered by the government departments including NH and the Biomedical Advanced Research and Development Authority (BARDA) to small-scale industries and companies that are focusing on developing novel products.  Hence, such factors are expected to drive market in the region during the forecast period.

Buy Now Full Report and Discover More

Key Cell Therapy Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Astellas Pharma Inc: The company offers ASP7317 for the treatment of dry AMD

• Athersys Inc.
• Avita Medical Inc
• BioCardia Inc.
• BioSenic SA
• Brainstorm Cell Therapeutics Inc.
• Bristol Myers Squibb Co.
• Capricor Therapeutics Inc.
• Castle Creek Biosciences Inc.
• CellSeed Inc.
• Cellular Biomedicine Group Inc.
• Celyad Oncology SA
• Gilead Sciences Inc.
• Lineage Cell Therapeutics Inc.
• Lisata Therapeutics Inc.
• Mesoblast Ltd.
• Novartis AG
• Pharmicell Co. Ltd.
• Sanpower Group Co. Ltd.
• ThermoGenesis Holdings Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics

The Diseseas Mechanisms and Treatment Foundation (DMTF) reports that the Cell Therapy market is experiencing significant growth, driven by advances in technology and research. Producers of cell therapies, such as Diseseas Mechanisms and Treatment (Disease), are developing new methods for the production and delivery of these therapies. For instance, Diseaseas is utilizing its proprietary technology to create a population of functional cells for use in cell therapy. The global Cell Therapy market is expected to grow considerably, with a focus on areas like gene therapy, cellular immunotherapy, and regenerative medicine. The use of cell therapies in these areas is revolutionizing the treatment of various diseases, including cancer and neurological disorders. The Climate, Cell, and Life Sciences Alliance (C-CSLA) and the Guideline Implementation Network (G-IN) are also playing crucial roles in the progress of cell therapy research and development. The treatment of various diseases, such as types and research, is a key focus of the Cell Therapy market. Virus-based outbreaks, such as COVID-19, have further highlighted the importance of cell therapies in the development of effective treatments. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Market Drivers

One of the key factors driving the market growth is the proven effectiveness of CAR T-cell therapy. There is an increasing preference for VAR-T cell therapies as it tends to have high efficacy when compared to other therapies that exist in the market for the treatment of cancer. The market is experiencing significant growth due to the limitations and risks associated with conventional organ transplantation. With the increasing demand for kidney transplants, accounting for over 80% of the total transplants in 2020, the need for alternative solutions is paramount. Horizon Europe is investing in personalized medicine, including stem cell therapy, to address chronic conditions such as insulin-dependent diabetes. Companies like Sernova and Evotec are pioneering the use of adult stem cells and cord blood processing to develop novel therapeutic regimes.

The cell therapy industry is leveraging automation, genetic editing tools like CRISPR-Cas9, and collaborations with research institutes and pharmaceutical giants such as EMA, Panacell Biotech, and Cellino Biotech. The Autologous therapy segment is gaining traction, with FDA approval for CAR-T therapies for genetic disorders. The Oncology segment, including treatments for acute lymphocytic leukemia, is also a significant market. However, challenges remain, including the limited availability of human cells and the need for a suitable composition and architecture of target tissue. Clinical studies are ongoing to explore the potential of cell therapy in treating musculoskeletal disorders, immune response, and graft-versus-cancer effect. Despite these advancements, challenges such as immunosuppressive therapies and the graft-versus-host effect persist. New therapeutic regimes, such as ALLO-501, are under development to address these challenges. In summary, the cell therapy market is growing due to the limitations of conventional organ transplantation and the potential of personalized medicine and stem cell therapy to address chronic conditions and regenerative medicine. Companies are investing in automation, genetic editing tools, and collaborations to develop novel therapeutic regimes for various indications, including oncology and musculoskeletal disorders. Challenges remain, but ongoing research and clinical studies are addressing these issues. Hence, such factors are positively impacting the market which, in turn, will drive the market growth during the forecast period.

Market Trends

A key factor shaping the market growth is the rise in vaccine production. There is increasing adoption of vaccines as it helps in the prevention of infectious diseases including diphtheria, hepatitis B, and measles. Vaccines are considered one of the cost-effective and successful strategies for precaution against health. 

The market encompasses various types of cells, including progenitor cells, adult and embryonic stem cells, and iPS cells, which have shown effectiveness in treating chronic conditions such as heart failure, cancer, and diabetes. The European Union's Horizon Europe initiative supports research in personalized medicine, including stem cell therapy. Sernova and Evotec are key players in insulin-dependent diabetes research using adult stem cells and cord blood processing. Newborn stem cells from umbilical cord blood are also being explored. Automation and genetic editing tools like CRISPR-Cas9 are revolutionizing the cell therapy industry. The European Medicines Agency (EMA) and FDA have approved autologous therapy segment products, such as PROVENGE by Dendreon, for cancer treatment.

Novartis and Opexa are also developing autologous cell therapy-based products. The oncology segment includes CAR-T therapies for genetic disorders, with FDA approval for ALLO-501 by Allogeneic therapies. Research institutes and pharmaceutical giants, such as Panacell Biotech and Cellino Biotech, are collaborating on clinical studies for musculoskeletal disorders and pneumonia treatments. Pharmaceutical and biotechnology companies are exploring novel therapeutic regimes in regenerative medicine for chronic conditions. As a result, there is a constant requirement for cell therapies for the regular supply of the same cell that can produce high-quality vaccines. Hence, such factors are positively impacting the market which in turn will drive the market growth during the forecast period.

Market Challenges

High cost and failure rates in clinical trials are the key challenges hindering market growth. Several market players in developed countries such as the US, the UK, Germany, France, Japan, Singapore, and South Korea are conducting clinical trials of cell therapy products. The cost of clinical trials is high in these regions as these are high-income countries. The market encompasses advanced treatments like stem cell therapy and personalized medicine. European initiatives, such as Horizon Europe, support research in this sector. Notable companies, including Sernova and Evotec, focus on insulin-dependent diabetes using adult stem cells and cord blood processing. New technologies like automation, genetic editing tools such as CRISPR-Cas9, and allogeneic therapies are driving innovation. Regulatory bodies like the EMA and FDA oversee approvals for autologous therapy segment, CAR-T therapies, and novel therapeutic regimes for genetic disorders.

Applications span from oncology segment, treating acute lymphocytic leukemia, to musculoskeletal disorders segment. Clinical studies on chronic conditions like diabetes and immune response are ongoing, with immunosuppressive therapies and the graft-versus-cancer effect being crucial factors. Notable therapies include ALLO-501 for pneumonia and insulin-dependent diabetes.

Moreover, several market players as well as startup biotech companies are increasingly relying on government or private funding. However, several organizations offer limited funds to market players till the target goal is completed. Hence, such constraints are negatively impacting the market which in turn will hinder the market growth during the forecast period.

Buy Now Full Report and Discover More

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Type Outlook
  • Autologous
  • Allogenic
• Application Outlook
  • Malignancies
  • Musculoskeletal
  • Cardiovascular
  • Others
• Geography Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Australia
    • Argentina
    • Brazil

Market Analyst Overview

The market refers to the growing industry of research, development, and application of cell-based therapies. These therapies utilize living cells to treat or prevent diseases and injuries. The market includes various types of cell therapies such as Stem Cell Therapies, Immunotherapies, and Gene Therapies. The Clinical Trials sector plays a crucial role in the Cell Therapy Market, as new treatments are continually being researched and developed. The market is also driven by the increasing demand for personalized treatments and the advances in technology that make cell therapies more effective and accessible. The Achilles Therapeutics and Horizon Therapeutics are some of the key players in the market, focusing on various therapeutic areas such as Oncology and Rare Diseases. The market is expected to grow significantly in the coming years due to the potential benefits of these innovative therapies. The regulatory environment, particularly in the US and Europe, is also evolving to support the development and commercialization of cell therapies.

The market is witnessing rapid growth, driven by advancements in Stem cell technologies and the development of novel Cell therapy approaches. Companies like Achilles Therapeutics and Calidi Biotherapeutics Inc. are pioneering Allogeneic cell therapy and exploring new Therapeutic regimes for various applications including Musculoskeletal, Malignancies, and Cardiovascular conditions.Key players like Bristol-Myers Squibb are leading the market with innovative products such as Breyanzi and Yescarta CAR T-cell therapy, which target CD19 and demonstrate the potential of CAR-T therapies. The market is also witnessing growth in Allogeneic Therapies Segment with the rise of Allogeneic Therapies.

Regulatory bodies like the Food and Drug Administration (FDA) play a crucial role in approving cell therapies, and ensuring their safety and efficacy. Clinical studies are being conducted to explore the potential of cell therapies in treating chronic conditions like Insulin-dependent diabetes. Overall, the global market is expanding rapidly, driven by the growing demand for Personalized medicine and the increasing acceptance of cell therapies as a viable treatment option for various diseases.

Market Scope
Report Coverage	Details
Page number	159
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 57.06%
Market growth 2023-2027	USD 31.04 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	56.5
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 40%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	Astellas Pharma Inc., Athersys Inc., Avita Medical Inc., BioCardia Inc., BioSenic SA, Brainstorm Cell Therapeutics Inc., Bristol Myers Squibb Co., Capricor Therapeutics Inc., Castle Creek Biosciences Inc., CellSeed Inc., Cellular Biomedicine Group Inc., Celyad Oncology SA, Gilead Sciences Inc., Lineage Cell Therapeutics Inc., Lisata Therapeutics Inc., Mesoblast Ltd., Novartis AG, Pharmicell Co. Ltd., Sanpower Group Co. Ltd., and ThermoGenesis Holdings Inc.
Market dynamics	Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch